Viewing data from:

FOSAPREPITANT DIMEGLUMINE

ANDA

FOSAPREPITANT DIMEGLUMINE | A209965 | MSN LABORATORIES PRIVATE LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: EMEND(TE code: AP)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
MERCK SHARP & DOHME CORP. v. MSN LABORATORIES PRIVATE LTD. et al 3:2018cv00675 1 patentANDA 209965fosaprepitant dimeglumine	D.N.J.	2018-01-16	Terminated 2018-07-11	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

API Supply Chain16 active DMFs2 inactive

16 active API suppliers hold Drug Master Files for this ingredient.

HETERO DRUGS LTDFOSAPREPITANT DIMEGLUMINE

DMF 256142011

MSN LABORATORIES PRIVATE LTDFOSAPREPITANT DIMEGLUMINE [ROUTE CODE - "FD"]

DMF 256822012

ALIVUS LIFE SCIENCES LTDFOSAPREPITANT DIMEGLUMINE

DMF 289922015

WOCKHARDT BIO AGFOSAPREPITANT DIMEGLUMINE

DMF 301372015

SCINOPHARM TAIWAN LTDFOSAPREPITANT DIMEGLUMINE

DMF 309732017

APITORIA PHARMA PRIVATE LTDFOSAPREPITANT DIMEGLUMINE

DMF 314702017

PIRAMAL PHARMA LTDFOSAPREPITANT DIMEGLUMINE

DMF 314842017

NAVINTA LLCFOSAPREPITANT DIMEGLUMINE

DMF 331052018

SHANDONG ANXIN PHARMACEUTICAL CO LTDFOSAPREPITANT DIMEGLUMINE (NON-STERILE API)

DMF 331422018

VIWIT PHARMACEUTICAL CO LTDFOSAPREPITANT DIMEGLUMINE

DMF 335582019

WISDOM PHARMACEUTICAL CO LTDFOSAPREPITANT DIMEGLUMINE

DMF 357662021

GLAND PHARMA LTDFOSAPREPITANT DIMEGLUMINE

DMF 378772023

DR REDDYS LABORATORIES LTDFOSAPREPITANT DIMEGLUMINE

DMF 382102023

MAHI DRUGS PRIVATE LTDFOSAPREPITANT DIMEGLUMINE

DMF 387312023

BIOPHORE INDIA PHARMACEUTICALS PVT LTDFOSAPREPITANT DIMEGLUMINE

DMF 404682024

SHANDONG NEW TIME PHARMACEUTICAL CO LTDFOSAPREPITANT DIMEGLUMINE

DMF 423412025

DR REDDYS LABORATORIES LTDInactiveFOSAPREPITANT DIMEGLUMINE

DMF 248292011

WISDOM PHARMACEUTICAL CO LTDInactiveFOSAPREPITANT DIMEGLUMINE

DMF 336792019

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 150MG BASE/VIAL

0 patents0 exclusivities▴

POWDER;INTRAVENOUS | Approved: Sep 5, 2019

No patent or exclusivity listings for this strength.